Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Crispr Therapeutics Ag (CRSP)

Crispr Therapeutics Ag (CRSP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,220,049
  • Shares Outstanding, K 55,204
  • Annual Sales, $ 3,120 K
  • Annual Income, $ -164,980 K
  • 60-Month Beta 3.20
  • Price/Sales 15.03
  • Price/Cash Flow N/A
  • Price/Book 5.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.04
  • Number of Estimates 3
  • High Estimate 0.07
  • Low Estimate 0.01
  • Prior Year -0.92
  • Growth Rate Est. (year over year) +104.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
57.21 +1.96%
on 01/02/20
70.00 -16.67%
on 12/23/19
-7.62 (-11.55%)
since 12/17/19
3-Month
37.21 +56.76%
on 10/18/19
74.00 -21.18%
on 12/04/19
+20.42 (+53.86%)
since 10/17/19
52-Week
29.34 +98.81%
on 02/07/19
74.00 -21.18%
on 12/04/19
+22.45 (+62.57%)
since 01/17/19

Most Recent Stories

More News
SCANS: The FAANG of The Roaring 20s

A new acronym of equities that could define the next decade of investing.

BABA : 227.43 (+1.56%)
SPLK : 157.96 (-1.47%)
SE : 41.28 (+0.78%)
NVDA : 249.28 (+0.14%)
CRSP : 58.33 (-2.18%)
The Zacks Analyst Blog Highlights: Sea Limited, CRISPR, Alibaba, Nvidia and Splunk

The Zacks Analyst Blog Highlights: Sea Limited, CRISPR, Alibaba, Nvidia and Splunk

BABA : 227.43 (+1.56%)
SPLK : 157.96 (-1.47%)
SE : 41.28 (+0.78%)
NVDA : 249.28 (+0.14%)
CRSP : 58.33 (-2.18%)
SNACS: The FAANG Of The Roaring 20s

SNACS: The FAANG Of The Roaring 20s

SPLK : 157.96 (-1.47%)
SE : 41.28 (+0.78%)
NVDA : 249.28 (+0.14%)
NFLX : 339.67 (+0.31%)
GOOGL : 1,479.52 (+2.02%)
FB : 222.14 (+0.17%)
CRSP : 58.33 (-2.18%)
BABA : 227.43 (+1.56%)
AMZN : 1,864.72 (-0.70%)
AAPL : 318.73 (+1.11%)
CRISPR Therapeutics to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top Conference

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive...

CRSP : 58.33 (-2.18%)
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

CRISPR Therapeutics AG (CRSP) closed at $59.44 in the latest trading session, marking a +0.2% move from the prior day.

CRSP : 58.33 (-2.18%)
Stocks Rally Into 2020

Stocks Rally Into 2020

CRSP : 58.33 (-2.18%)
ENPH : 31.50 (+2.17%)
RH : 222.39 (-0.40%)
RUBI : 10.13 (-1.75%)
SMPL : 25.19 (+0.92%)
CNC : 64.54 (-0.91%)
What the Tech?

Let's REALLY dive deep into the abyss which can be tech. Associate Stock Strategist Dan Laboe, Zacks' resident Tech geek joins us.

TSLA : 510.50 (-0.58%)
MSFT : 167.10 (+0.56%)
TSM : 58.58 (-0.29%)
CRSP : 58.33 (-2.18%)
Find Strong Stocks Heading into 2020 with this First Profit Screen

Find Strong Stocks Heading into 2020 with this First Profit Screen

SPWR : 8.77 (-0.23%)
EGO : 7.26 (-2.02%)
CRSP : 58.33 (-2.18%)
BEST : 6.41 (+0.63%)
AG : 10.53 (-4.71%)
Global CRISPR Technology Market Report 2019-2025 with Analysis of Key Companies - Thermo Fisher Scientific, Merck KGaA, GenScript Biotech, Horizon Discovery Group, CRISPR Therapeutics - ResearchAndMarkets.com

The "Global CRISPR Technology Market 2019-2025" report has been added to ResearchAndMarkets.com's offering.

CRSP : 58.33 (-2.18%)
GNNSF : 2.3000 (-4.56%)
HZNQF : 1.9300 (-0.52%)
Black Diamond Therapeutics Closes $85 Million Series C Financing

Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the completion of an oversubscribed...

CRSP : 58.33 (-2.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CRSP with:

Business Summary

CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

See More

Key Turning Points

2nd Resistance Point 61.28
1st Resistance Point 59.80
Last Price 58.33
1st Support Level 57.33
2nd Support Level 56.34

See More

52-Week High 74.00
Last Price 58.33
Fibonacci 61.8% 56.94
Fibonacci 50% 51.67
Fibonacci 38.2% 46.40
52-Week Low 29.34

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar